Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Chronocort

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Neurocrine UK

Phase 3 Most advanced trial (none active)

NBIX Developer

2 Registered trials

What is Chronocort?

Chronocort is a modified-release oral capsule formulation of hydrocortisone designed for once-daily dosing in congenital adrenal hyperplasia. It delivers hydrocortisone to mimic the body's natural circadian cortisol rhythm, acting as a glucocorticoid receptor agonist to suppress adrenal androgen production.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1)
Mechanism: Agonist of glucocorticoid receptor (NR3C1)
Pathways: HPA axis suppression
Therapy area: Endocrine
Developer: Neurocrine UK Limited (NBIX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05063994	Phase 3	Congenital Adrenal Hyperplasia	Completed	NBIX
NCT03532022	Phase 3	Congenital Adrenal Hyperplasia	Withdrawn	NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital Adrenal Hyperplasia

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Exicorilant Phase 1/2 Miricorilant Phase 2 ORIC-101 Phase 1

More from Neurocrine UK

Crinecerfont FDA approved Valbenazine FDA approved DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1070770 Phase 2 NBI-1117567 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind Chronocort

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z